Drugs assessed by IQWiG
Since early 2011, the added benefit of most medications containing new active ingredients must be assessed as soon as they enter the market in German...
Read more
The price of new drugs in Germany depends on the result of the so-called early benefit assessment. The legal basis for this is the “Act on the Reform of the Market for Medicinal Products (AMNOG).” Here you can find information on medications that have been assessed by the German Institute for Quality and Efficiency in Health Care (IQWiG, Germany) in the last few years.
Early benefit assessment of medications from A to Z
